Everything below concerns thymalfasin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-25. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
== History == Apixaban was approved for medical use in the European Union in May 2011. A new drug application (NDA) for the approval of apixaban was submitted to the US Food and Drug Administration (FDA) by Bristol-Myers Squibb (BMS) and Pfizer jointly after the conclusion of the ARISTOTLE clinical trial in 2011. Apixaban was approved for the prevention of stroke in people with atrial fibrillation in December 2012. In March 2014, it was approved for the additional indication of preventing deep vein thrombosis and pulmonary embolism in people who have recently undergone knee or hip replacement. In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism. During its development the drug was known as BMS-562247-01. By late 2019, sales of the product by BMS accounted for thirty percent of their quarterly revenue.
Pyruvate:ferredoxin oxidoreductase, which converts pyruvate into acetyl-CoA and CO2 while reducing the ferredoxin. Hydrogenase, which converts H+ into H2 while oxidizing the ferredoxin. Acetyl-CoA synthetase (in reverse), which converts acetyl-CoA and ADP + Pi into acetate, coenzyme A, and ATP. (A variant of the reaction uses acetate:succinate CoA transferase and succinyl-CoA synthatase in reverse.) The net reaction is conversion of singular equivalents of pyruvate, ADP, and Pi into ATP, CO2, acetate, and H2.
Controversy soon arose over the size of UNTAG's military component, as the member states of the Security Council expected to cover the majority of the costs were irritated by its relatively large size. However, Angola, Zambia, and other states sympathetic to PLAN insisted that a larger force was necessary to ensure that South Africa did not interfere with independence proceedings. Against their objections UNTAG's force levels were reduced from the proposed 7,500 to three battalions of 4,650 troops. This slashed projected expenses by nearly 300 million dollars, but the Security Council did not approve the revised budget until 1 March 1989. The inevitable delay in UNTAG's full deployment ensured there were insufficient personnel prepared to monitor the movement of PLAN and the SADF or their confinement to bases on 1 April 1989, when the permanent cessation in hostilities was to take effect. Secretary-General de Cuéllar urged restraint in the interim on both sides to avoid jeopardising the de facto ceasefire maintained since August 1988 or the 1 April implementation schedule. Nevertheless, PLAN took advantage of the political uncertainty in the weeks following the UNTAG budget debate to begin moving its forces in Angola closer to the border. Since the early 1980s PLAN had consistently stated its intention to establish camps inside South West Africa during any future political transition, a notion rejected with equal consistency by the South African government.
Sources: en.wikipedia.org
The field of metagenomics involves identification of organisms present in a body of water, sewage, dirt, debris filtered from the air, or swab samples from organisms. Knowing which organisms are present in a particular environment is critical to research in ecology, epidemiology, microbiology, and other fields. Sequencing enables researchers to determine which types of microbes may be present in a microbiome, for example.
The fate of Neo was never truly revealed in the MMORPG sequel, The Matrix Online; however, despite this, his influence had a strong impact on several key events throughout the game. In the beginning, scattered code fragments of Neo's "RSI" (Residual Self Image) were found on the bodies of the impostor agents; who appeared across the Mega City during Chapter 1.1 (later revealed to be sentinels under the command of the general program) when held, these fragments echoed some of the final thoughts of Neo inside the redpill's mind. Each of the three main post-war political organizations inside the Matrix realized the possible significance of these fragments and began fighting amongst themselves to gather as many as they could. The Oracle reveals a secret society of exiles known only as the Shapers, who are the only ones able to bring the Fragments together in any significant way and that they must be protected from the impostor agents' corruption. The redpills' distrust and organizational differences prove too much for any strong unity, so that a shaper fell into the captivity of the false agents. His power was used to encode some part of the One's being onto them, creating the powerful, pale-skinned "N30 Ag3nts". In Chapter 1.2, Morpheus states that though the machines never returned Neo's physical remains (Neo's body in the real world) to Zion, they did not "recycle" them; a reference to the first film, in which Morpheus tells Neo that the machines liquefy deceased occupants of the Matrix to provide organic sustenance for its living inhabitants.
== Types == Fomentations – heated poultices – may be used to promote blood circulation to an affected area; these may be unmedicated. Cold poultices are sometimes used. An example is the use of cabbage leaves to reduce breast engorgement in breastfeeding mothers. The leaves are applied directly to the breast, often simply held in place by a bra. Evidence for effectiveness as a treatment is weak: cabbage poultices are about as effective as the frequent, unrestricted feeding of the infant; they have no effect on the rate of progression to mastitis. There is some slight evidence that cabbage poultices reduce the pain of engorgement.
Sources: en.wikipedia.org
== Diagnosis == An earlier diagnosis of IPF is a prerequisite for earlier treatment and, potentially, improvement of the long-term clinical outcome of this progressive and ultimately fatal disease. If IPF is suspected, diagnosis can be challenging but a multidisciplinary approach involving a pulmonologist, radiologist and pathologist expert in interstitial lung disease has been shown to improve the accuracy of IPF diagnosis. A Multidisciplinary Consensus Statement on the Idiopathic Interstitial Pneumonias published by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) in 2000 proposed specific major and minor criteria for establishing the diagnosis of IPF. However, in 2011, new simplified and updated criteria for the diagnosis and management of IPF were published by the ATS, ERS, together with the Japanese Respiratory Society (JRS) and Latin American Thoracic Association (ALAT). Currently, a diagnosis of IPF requires:
=== Flavodoxin-1 domain === Flavoproteins are ubiquitous biocatalysts binding specific redox active prosthetic groups. The domain is associated with electron transfer proteins and used in electron transport systems. The cofactor flavin-mononucleotide (FMN) is bound non-covalently to the domain, which is functionally interchangeable with iron-sulfur constituted proteins regulating electron transfer or ferredoxins.
SDS-PAGE is an electrophoresis method that allows protein separation by mass. The medium (also referred to as ′matrix′) is a polyacrylamide-based discontinuous gel. The polyacrylamide-gel is typically sandwiched between two glass plates in a slab gel. Although tube gels (in glass cylinders) were used historically, they were rapidly made obsolete with the invention of the more convenient slab gels. In addition, SDS (sodium dodecyl sulfate) is used. About 1.4 grams of SDS bind to a gram of protein, corresponding to one SDS molecule charges per two amino acids. SDS acts as a surfactant, masking the protein's intrinsic charge and conferring them very similar charge-to-mass ratios. The intrinsic charges of the proteins are negligible in comparison to the SDS loading, and the positive charges are also greatly reduced in the basic pH range of a separating gel. Upon application of a constant electric field, the proteins migrate towards the anode, each with a different speed, depending on their mass. This simple procedure allows precise protein separation by mass. SDS tends to form spherical micelles in aqueous solutions above a certain concentration called the critical micelle concentration (CMC). Above the critical micellar concentration of 7 to 10 millimolar in solutions, the SDS simultaneously occurs as single molecules (monomer) and as micelles, below the CMC SDS occurs only as monomers in aqueous solutions. At the critical micellar concentration, a micelle consists of about 62 SDS molecules.
All living cells have the ability to receive and process signals that originate outside their membranes, which they do by means of proteins called receptors, often located at the cell's surface imbedded in the plasma membrane. When such signals interact with a receptor, they effectively direct the cell to do something, such as dividing, dying, or allowing substances to be created, or to enter or exit the cell. A cell's ability to respond to a chemical message depends on the presence of receptors tuned to that message. The more receptors a cell has that are tuned to the message, the more the cell will respond to it. Receptors are created, or expressed, from instructions in the DNA of the cell, and they can be increased, or upregulated, when the signal is weak, or decreased, or downregulated, when it is strong. Their level can also be up or down regulated by modulation of systems that degrade receptors when they are no longer required by the cell. Downregulation of receptors can also occur when receptors have been chronically exposed to an excessive amount of a ligand, either from endogenous mediators or from exogenous drugs. This results in ligand-induced desensitization or internalization of that receptor. This is typically seen in animal hormone receptors. Upregulation of receptors, on the other hand, can result in super-sensitized cells, especially after repeated exposure to an antagonistic drug or prolonged absence of the ligand.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.